In Jilin, China on July 21, 2026, Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT), a veterinary vaccine manufacturer specializing in research, development, manufacturing, and sales of veterinary vaccines, especially focusing on livestock vaccines in China, addressed recent abnormal trading in its Class A ordinary shares.